---

市場概況

---

The global next-generation biomanufacturing market is forecasted to grow at a CAGR of 14.85% から 2021 に 2031, の値に達する $85.20 億で 2031.

Biomanufacturing involves the production of biomolecules using biological systems for applications in medicine, 食品および飲料の加工, and industry. Natural sources such as blood, microbial cultures, animal cells, and plant cells are commonly used in biomanufacturing, and genetic engineering techniques can also be employed to obtain cells for production purposes.

The research study titled Global Next-Generation Biomanufacturing Market focuses on understanding the key trends in next-generation biomanufacturing, specifically the use of single-use bioreactors and digital bioreactors worldwide. The study provides insights into the competitive landscape of the global market and analyzes market dynamics and regulatory frameworks affecting its growth across different regions. It also offers an in-depth analysis of the drivers, 課題, and opportunities in the market, with a focus on major countries in North America, ヨーロッパ, アジア太平洋地域, ラテンアメリカ, and the Rest-of-the-World.

The report is segmented based on workflow and product, medical application, エンドユーザー, と地域. Each chapter provides a comprehensive understanding of the products available in the global next-generation biomanufacturing market and the current trends within each domain. It also highlights key companies in each domain and their contributions to the market. さらに, the report covers detailed information on the emergence of automation in biomanufacturing, including different types of automation, current trends, and opportunities in the field.

Key drivers of market growth include the increasing approvals of biologics and biosimilars, the growing trend of integrating automation technologies among biomanufacturing vendors, and the aim to enhance bioproduction workflows while reducing costs, 時間, and labor.

Market challenges include complex production steps, operational complexity, the risk of product contamination, maintaining production efficiency, and validation challenges. さらに, the market faces a shortage of skilled professionals and lacks harmonized manufacturing standards and sufficient knowledge and skilled labor in middle-income and low-income countries.

Market opportunities lie in the increasing development and commercialization of digital bioreactors and the rising investment in research and development along with the rapid growth of the biopharmaceutical industry.

---

市場セグメンテーション

---

市場はさまざまな要因に基づいて分割されます, including workflow, 製品, medical application, エンドユーザー, と地域.

Segmentation by Workflow
Upstream Biomanufacturing
Downstream Biomanufacturing

製品ごとのセグメンテーション
Continuous Upstream Biomanufacturing Products
Single-Use Upstream Biomanufacturing Products
Downstream Biomanufacturing Products

Segmentation by Medical Application
モノクローナル抗体
Hormones
ワクチン
Recombinant Proteins
その他の用途

エンドユーザーごとのセグメンテーション
Biopharmaceutical Companies
CMO/CDMO
Research Institutions

地域ごとのセグメンテーション
北米 – 私たち. そしてカナダ
ヨーロッパ – イギリス。, ドイツ, フランス, イタリア, スペイン, アイルランド, スイス, ロシア, およびヨーロッパのその他の地域
アジア太平洋地域 – 中国, 日本, インド, 韓国, オーストラリア, シンガポール, およびその他のアジア太平洋地域
ラテンアメリカ – ブラジル, メキシコ, アルゼンチン, and Rest-of-Latin America
世界のその他の地域

In the global next-generation biomanufacturing market, the upstream biomanufacturing segment currently holds the dominant position in terms of workflow. This is due to the significant investment required for expensive equipment in upstream biomanufacturing compared to downstream biomanufacturing. しかし, the downstream biomanufacturing segment is expected to experience higher growth in the forecast period. This is primarily attributed to continuous product innovations in chromatography and filtration systems used in downstream processing.

の 2020, continuous upstream biomanufacturing accounted for 85.93% of the global next-generation biomanufacturing market. It was valued at $10,207 million and is projected to reach $37,855 百万までに 2031, CAGR は 12.74%. The wide availability and high adoption rate of products used in continuous upstream biomanufacturing contribute to its market dominance. しかし, there is a shift towards the use of single-use equipment, which is expected to drive the growth of single-use biomanufacturing equipment. The single-use upstream biomanufacturing segment is anticipated to have a higher CAGR of 21.79% の予測期間中に 2021-2031. This shift is motivated by the advantages of single-use equipment, such as space-saving, flexibility in scale, and cost savings in development and changeover processes.

Biomanufacturing plays a crucial role in producing various medically important biological products, including amino acids, ワクチン, 成長因子, and monoclonal antibodies. The increasing demand for these products is driven by the need to target different diseases and cater to a growing patient population. Biopharmaceutical and biotechnology companies are focusing on improving productivity, yield, and reducing facility complexity and cost of goods to meet market demands.

Among the different medical application areas, monoclonal antibodies hold the largest share in the global next-generation biomanufacturing market, contributing 44.62% で 2020. The monoclonal antibodies segment was valued at $8,368 million and is expected to reach $36,218 百万までに 2031, CAGR は 12.96%. The increasing commercialization and approval rate of monoclonal antibody products, along with the entry of more companies offering these products, contribute to its growth. Recombinant proteins are expected to have the highest CAGR of 14.27% due to the expanding research activities in genetic engineering, leading to a wide range of recombinant protein products.

In terms of end users, the global next-generation biomanufacturing market is concentrated around Contract Research Organizations (CRO)/Contract Manufacturing Organizations (CMO), バイオ医薬品会社, and research centers. Based on the stage of product development, end users are classified into commercial stage and preclinical/development stage. Commercial stage end users have received regulatory approval for product commercialization, while preclinical/development stage end users are still in the pipeline or preclinical stage.

Among the different types of organizations associated with commercial and preclinical/development stages, biopharmaceutical companies lead in both categories. The dominance of biopharmaceutical companies is attributed to their reliance on biomanufacturing for product development and the increasing trend of pharmaceutical companies transforming into biopharmaceutical ones. The global next-generation market for commercial stage biopharmaceutical companies was valued at $9,559 百万で 2020 and is expected to reach $40,534 百万までに 2031, CAGR は 14.73%. The market for preclinical/development stage biopharmaceutical companies was valued at $2,160 百万で 2020 and is expected to reach $10,740 百万までに 2031, CAGR は 15.26%.

North America emerged as the leading region in the global next-generation biomanufacturing market in 2020. It benefits from well-equipped facilities, advanced infrastructure, and significant investments in biomanufacturing. The expanding biopharmaceuticals and biologics industry in North America attracts investors and presents growth opportunities. The presence of key industry players further strengthens the market in this region.

Asia-Pacific is expected to witness the highest CAGR during the forecast period. This growth is driven by emerging nations such as Japan, インド, オーストラリア, 韓国, そしてシンガポール, which are adopting technologically advanced biomanufacturing equipment. The installation of new capacities in response to growing product demand in these countries contributes to the growth of the next-generation biomanufacturing market in Asia-Pacific.

---

競争環境

---

Prominent players in the next-generation biomanufacturing market include Applikon Biotechnology BV, bbi-biotech GmbH, ダナハーコーポレーション, Eppendorf AG, Esco Group of Companies, GEA Group Aktiengesellschaft, Meissner Filtration Products, 株式会社, メルクKGaA, PBS Biotech, 株式会社, Pierre Guérin, Sartorius AG, Shanghai Bailun Biotechnology Co. 株式会社, Solaris Biotechnology Srl, Thermo Fisher Scientific Inc., and ZETA GmbH. The COVID-19 pandemic had a significant impact on the bioprocess segment of companies like GE Healthcare, resulting in lower revenue in 2020 due to supply-demand imbalances. しかし, key players like Danaher Corporation experienced high revenue growth due to strong demand for bioprocess solutions.

The global next-generation biomanufacturing market is experiencing exponential growth, driven by substantial investments from public and private sectors to develop advanced biomanufacturing facilities. Automation technologies are increasingly adopted in the industry, offering advantages such as improved speed, productivity, and accuracy. The market for automation systems is growing rapidly, with more companies investing in and launching new automation solutions.

Between 2017 と 2021, the next-generation biomanufacturing market witnessed approximately 115 key developments related to biomanufacturing and automation. These developments included acquisitions, パートナーシップ, and collaborations by major companies. 例えば, 2月中 2020, ハネウェル・インターナショナル株式会社. collaborated with Bigfinite, 株式会社. to enhance process automation and control technology using Bigfinite’s AI, データ分析, and machine learning platform, benefiting the pharmaceutical and biotech industries. 3月 2019, Rockwell Automation and GE Healthcare entered into a collaborative agreement to combine their expertise in automation and single-use solutions to develop digital bioprocessing operations.

---

主な質問への回答

---

What are the primary trends driving the global next-generation biomanufacturing market?

How is the market evolving, and what are the future prospects for its growth?

What role does automation play in the field of biomanufacturing?

What are the main drivers, 課題, and opportunities in the global next-generation biomanufacturing market?

What is the regulatory framework governing the global next-generation biomanufacturing market?

What is the market share of each player offering products for next-generation biomanufacturing?

What strategies do major players implement to remain competitive in the global next-generation biomanufacturing market?

What was the market size of the global next-generation biomanufacturing market in 2020, and what is the projected market size for 2031?

What is the expected growth rate of the global next-generation biomanufacturing market between 2021 と 2031?

What are the different next-generation biomanufacturing products used in the medical field?

Which product segment is anticipated to have the highest compound annual growth rate (CAGR) の予測期間中に 2021-2031?

What are the key medical applications for the global next-generation biomanufacturing market?

Which application type is expected to witness the highest growth rate during the forecast period of 2021-2031?

Who are the major end users in the global next-generation biomanufacturing market?

What were the market shares held by each end user in the global next-generation biomanufacturing market in 2020?

What are the expected growth rate and market shares by 2031?

What were the market values of the leading segments and sub-segments of the global next-generation biomanufacturing market in 2020, and what are the projected values for 2031?

What are the macro and microeconomic factors influencing the growth of the market?

Which region dominated the global next-generation biomanufacturing market in 2020?

Which geographic regions present potential target markets for significant expansion of key companies in different next-generation biomanufacturing products?

Which key countries contribute significantly to the growth of the next-generation biomanufacturing market?

Who are the major players in the global next-generation biomanufacturing market, そしてそれらは市場でどのような役割を果たしているのか?

Who are the leading players in the single-use bioreactor market?